Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refining prognostication in systemic AL amyloidosis: limited value of dFLC.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, Venneri L, Fontana M, Whelan C, Hawkins PN, Gillmore JD, Lachmann HJ, Mahmood S, Wechalekar A. Khwaja J, et al. Among authors: mahmood s. Amyloid. 2024 Dec;31(4):353-355. doi: 10.1080/13506129.2024.2406845. Epub 2024 Sep 23. Amyloid. 2024. PMID: 39311543 No abstract available.
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, Gillmore J, Pitchford A, Oughton JB, Mahmood S, Sachchithantham S, Hawkins P, Brown S, Wechalekar A. Ravichandran S, et al. Among authors: mahmood s. Amyloid. 2023 Sep;30(3):290-296. doi: 10.1080/13506129.2023.2169124. Epub 2023 May 22. Amyloid. 2023. PMID: 37216268 Clinical Trial.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: mahmood s. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf MU, Foard D, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore J, Lachmann H, Mahmood S, Wechalekar AD. Bomsztyk J, et al. Among authors: mahmood s. Br J Haematol. 2024 Jul;205(1):138-145. doi: 10.1111/bjh.19529. Epub 2024 Jun 5. Br J Haematol. 2024. PMID: 38840512
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, Rauf MU, Sinigiani G, Wisniowski B, Filisetti S, Currie-Cathey J, O'Beara S, Kotecha T, Knight D, Moon JC, Sinagra G, Virsinskaite R, Gilbertson J, Venneri L, Petrie A, Lachmann H, Whelan C, Kellman P, Ravichandran S, Cohen O, Mahmood S, Manisty C, Hawkins PN, Gillmore JD, Wechalekar AD, Fontana M. Porcari A, et al. Among authors: mahmood s. JAMA Cardiol. 2024 Nov 1;9(11):982-989. doi: 10.1001/jamacardio.2024.2555. JAMA Cardiol. 2024. PMID: 39167388 Free PMC article.
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, Fernandes S, Taylor J, Paterson P, Brearton G, Crawley C, Sheehy O, Brown R, Soutar R, Garg M, Rydzewski A, Jamroziak K, Mahmood S, Wechalekar AD. Khwaja J, et al. Among authors: mahmood s. Br J Haematol. 2024 May;204(5):1811-1815. doi: 10.1111/bjh.19286. Epub 2024 Jan 3. Br J Haematol. 2024. PMID: 38171355
Haematopoietic stem cell mobilisation followed by high-dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma.
Asher S, Shah R, Ings S, Horder J, Newrick F, Nesr G, Kesse Adu R, Streetly M, Trompeter S, Lee L, Wisniowski B, Mahmood S, Xu K, Papanikalaou X, McMillan A, Popat R, Yong K, Sive J, Kyriakou C, Rabin N. Asher S, et al. Among authors: mahmood s. Br J Haematol. 2023 Sep;202(6):1224-1227. doi: 10.1111/bjh.18990. Epub 2023 Jul 24. Br J Haematol. 2023. PMID: 37488061 No abstract available.
1,759 results